New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma
Pharmacy Times
JUNE 27, 2025
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.
Let's personalize your content